RedHill Biopharma (NASDAQ:RDHL) Ltd (NASDAQ:RDHL) chief business officer Guy Goldberg caught up with Proactive New York to speak on results of its new preclinical study, which he says demonstrated strong inhibition by its investigational oral pill opaganib of the coronavirus Delta variant replication while maintaining cell viability at relevant concentrations.
Goldberg says opaganib was studied in a 3D tissue model of human bronchial epithelial cells (EpiAirway) to evaluate the in vitro efficacy of opaganib in inhibiting the Delta (Indian) variant. RedHill said this adds to the previously reported work that showed opaganib also inhibits Beta (South African) and Gamma (Brazilian) SARS-CoV-2 variants.